LLY

994.01

-1.48%↓

JNJ

201.82

+0.01%↑

ABBV

224.15

-0.92%↓

UNH

324.14

-1.93%↓

AZN

90.51

+0.37%↑

LLY

994.01

-1.48%↓

JNJ

201.82

+0.01%↑

ABBV

224.15

-0.92%↓

UNH

324.14

-1.93%↓

AZN

90.51

+0.37%↑

LLY

994.01

-1.48%↓

JNJ

201.82

+0.01%↑

ABBV

224.15

-0.92%↓

UNH

324.14

-1.93%↓

AZN

90.51

+0.37%↑

LLY

994.01

-1.48%↓

JNJ

201.82

+0.01%↑

ABBV

224.15

-0.92%↓

UNH

324.14

-1.93%↓

AZN

90.51

+0.37%↑

LLY

994.01

-1.48%↓

JNJ

201.82

+0.01%↑

ABBV

224.15

-0.92%↓

UNH

324.14

-1.93%↓

AZN

90.51

+0.37%↑

Kodu・Aktsiate loetelu・Cassava Sciences Inc

Cassava Sciences Inc

Avatud

SektorTervishoid

3.24 1.57

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.12

Max

3.25

Põhinäitajad
By Trading Economics
Sissetulek	33M -11M
Müük	840K 840K
Aktsiakasum	-0.22
Kasumimarginaal	-1,286.548
Töötajad	30
EBITDA	35M -11M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+150.78% upside

Turustatistika
By TradingEconomics
Turukapital	-4.3M 142M
Eelmine avamishind	1.67
Eelmine sulgemishind	3.24

Uudiste sentiment

By Acuity

34%

66%

105 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

1.56 / 1.7 Toetus ja vastupanu

Cassava Sciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. dets 2025, 23:00 UTC

Omandamised, ülevõtmised, äriostud

Brookfield, GIC Agree $4.5 Billion Deal for Australia's National Storage -- Update

5. dets 2025, 21:08 UTC

Omandamised, ülevõtmised, äriostud

Meta Platforms Buys AI-Device Maker Limitless

5. dets 2025, 19:39 UTC

Suurimad hinnamuutused turgudel

Parsons' FAA Bid Loss Clouds Outlook After Rocky Year for Contractors

5. dets 2025, 19:17 UTC

Omandamised, ülevõtmised, äriostud

Constellation Energy Agrees to Divest Assets to Finalize Calpine Deal

7. dets 2025, 23:42 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

7. dets 2025, 23:05 UTC

Market Talk

RBA Set to Remain 'Emphatically' On Hold, Westpac Says -- Market Talk

7. dets 2025, 22:18 UTC

Market Talk

RBA Set To Conclude Year With Hawkish Message -- Market Talk

6. dets 2025, 16:52 UTC

Omandamised, ülevõtmised, äriostud

As Netflix Swoops In to Buy Warner Bros., We Revisit the Studio's Long, Twisted Journey -- Barrons.com

6. dets 2025, 10:30 UTC

Omandamised, ülevõtmised, äriostud

Why Netflix Shareholders Aren't Thrilled to Acquire Warner Bros. -- Heard on the Street -- WSJ

6. dets 2025, 02:38 UTC

Omandamised, ülevõtmised, äriostud

How a Netflix-Warner Deal Would Change Everything in Hollywood -- Again -- WSJ

5. dets 2025, 21:59 UTC

Omandamised, ülevõtmised, äriostud

Netflix's Megadeal Will Need the Trump Administration's Blessing -- Update

5. dets 2025, 21:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

5. dets 2025, 21:50 UTC

Omandamised, ülevõtmised, äriostud

The Netflix and Warner Bros. Deal Is Far From a Sure Thing -- Barrons.com

5. dets 2025, 21:36 UTC

Market Talk

Return of Shipping to Red Sea a Step Closer, Xeneta Says -- Market Talk

5. dets 2025, 21:35 UTC

Omandamised, ülevõtmised, äriostud

The Netflix-Warner Bros. Deal Has a Wildcard. How Paramount Could Still Win. -- Barrons.com

5. dets 2025, 21:26 UTC

Omandamised, ülevõtmised, äriostud

Warner Bros. Discovery and Netflix Enter Exclusive Deal Negotiations -- 7th Update

5. dets 2025, 21:12 UTC

Market Talk

Natural Gas Surge 9% This Week on Strong Flow of Exports -- Market Talk

5. dets 2025, 21:03 UTC

Market Talk

Tulu

Bank of Montreal Logs Solid Quarter, Though Some Unease Remains -- Market Talk

5. dets 2025, 21:01 UTC

Market Talk

Oil Caps Positive Week on Geopolitical Turmoil -- Market Talk

5. dets 2025, 20:43 UTC

Omandamised, ülevõtmised, äriostud

Limitless CEO Siroker: Will No Longer Sell Pendant to New Customers

5. dets 2025, 20:43 UTC

Omandamised, ülevõtmised, äriostud

Limitless CEO Siroker: Existing Pendant Customers to Be Supported for at Least Another Year

5. dets 2025, 20:42 UTC

Omandamised, ülevõtmised, äriostud

Limitless CEO Dan Siroker: Limitless Has Been Acquired by Meta >META

5. dets 2025, 20:01 UTC

Omandamised, ülevõtmised, äriostud

Netflix Landed a Big Deal. Now it Could Have a Big Fight. -- WSJ

5. dets 2025, 19:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. dets 2025, 19:44 UTC

Market Talk

Canada Dollar Gains Nearly 1% on Jobs Data, Rate Outlook -- Market Talk

5. dets 2025, 19:39 UTC

Market Talk

Silver Climbs to a New Record High -- Market Talk

5. dets 2025, 19:31 UTC

Omandamised, ülevõtmised, äriostud

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5. dets 2025, 18:30 UTC

Market Talk

Canada Jobless Rate Can Fall More Before Labor Slack Disappears -- Market Talk

5. dets 2025, 18:28 UTC

Omandamised, ülevõtmised, äriostud

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5. dets 2025, 18:24 UTC

Omandamised, ülevõtmised, äriostud

AMC and IMAX Stocks Drop. Roku Rises. How the Netflix-Warner Bros. Deal Could Shake Up Entertainment. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Cassava Sciences Inc Prognoos

Hinnasiht

By TipRanks

150.78% tõus

12 kuu keskmine prognoos

Keskmine 8 USD 150.78%

Kõrge 8 USD

Madal 8 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Cassava Sciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Cassava Sciences Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.56 / 1.7Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

105 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Cassava Sciences Inc

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.